RxDoctor Payments Data

Willaim Padilla, MD

Family Medicine · Chula Vista, CANPI 1972694792

Payments from drug & device makers

$404in general payments, 2019–2025

Across 20 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$94
  • Lilly USA, LLC$48
  • Edwards Lifesciences$42
  • Medtronic$34
  • Boehringer Ingelheim$26
  • Biotronik Inc.$26
  • plus $135 from 7 others

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$404 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$105,628
Medicare patients
223
Services billed
1,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin173$235,082
OzempicSemaglutide89$116,087
EliquisApixaban81$79,320
XifaxanRifaximin12$38,301
JanuviaSitagliptin Phosphate22$33,713
Evenity (2 Syringes)Romosozumab-Aqqg11$28,384
JanumetSitagliptin Phos/Metformin Hcl25$27,433
MyrbetriqMirabegron33$26,789
LinzessLinaclotide18$25,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,477
TrulicityDulaglutide19$22,354
XareltoRivaroxaban14$19,942
Spiriva RespimatTiotropium Bromide20$16,002
ArexvyRsvpref3 Antigen/As01e/Pf52$15,507
FarxigaDapagliflozin Propanediol12$14,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$26$251,084193 claims
Novo NordiskOzempic$94$116,08789 claims
MerckJanuvia, Janumet$17$61,14647 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$21$41,03187 claims
AmgenEvenity (2 Syringes)$16$28,38411 claims
Astellas Pharma US IncMyrbetriq$20$26,78933 claims
Lilly USA, LLCTrulicity$48$22,35419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →